Arch Biopartners (ARCH) AI Stock Analysis

• Market Cap: C$115.49M
• Dividend Yield: N/A
• Average Volume (3M): 9.60K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.19
• Revenue Growth: N/A
• EPS Growth: -78.59%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): -0.06
• Shares Outstanding: 65,621,370
• 10 Day Avg. Volume: 7,287
• 30 Day Avg. Volume: 9,599
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 51.50
• Price to Cash Flow (P/CF): -32.60
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Arch Biopartners is facing critical financial distress with no revenue, significant losses, and high leverage, leading to a low overall score. Technical analysis further suggests a bearish outlook, and the lack of profitability negatively impacts its valuation score. The combination of these factors results in a low stock score.

Arch Biopartners Business Overview & Revenue Model

Company Description

Arch Biopartners Inc. is a Canadian biotechnology company focused on developing innovative solutions to treat medical conditions with significant unmet needs. The company primarily operates within the sectors of life sciences and pharmaceuticals, with a core emphasis on creating proprietary technologies related to inflammation, organ protection, and cancer treatment. Arch Biopartners is dedicated to advancing its pipeline of drug candidates through clinical trials to bring new therapies to market.

How the Company Makes Money

Arch Biopartners generates revenue through the development and commercialization of its proprietary drug candidates. The company aims to progress its products through clinical trials, ultimately achieving regulatory approval for commercialization. Upon successful commercialization, revenue streams may include product sales, licensing agreements with larger pharmaceutical companies, and potential milestone payments or royalties. Additionally, the company may benefit from research grants or partnerships that provide funding support during the development phases. However, as of now, Arch Biopartners primarily relies on investment capital to support its research and development activities, with the expectation of future revenue generation upon successful drug approval and market entry.

Arch Biopartners Financial Statement Overview

Summary

Arch Biopartners exhibits severe financial challenges across all primary financial statements. The absence of revenue, large operational losses, negative equity, and reliance on financing indicate a precarious financial position. Strategic interventions are needed to stabilize and improve financial health.

Income Statement

Arch Biopartners is facing significant challenges in its income statement. The company has reported zero revenue in the latest year, indicating a complete halt in sales or service income. Historical data shows a declining trend in revenue with consistent losses, as evidenced by negative EBIT and net income margins. The lack of profitability and revenue growth are major concerns.

Balance Sheet

The balance sheet reflects a highly leveraged position with negative stockholders' equity, signaling financial instability. The debt-to-equity ratio cannot be calculated due to negative equity, which poses a significant risk. Total liabilities surpass total assets, indicating insolvency. There is a negative equity ratio, highlighting financial distress.

Cash Flow

Arch Biopartners has negative free cash flow, reflecting insufficient cash generation from operations to cover capital expenditures and operating needs. With no operating cash flow and continuous negative free cash flow, the company is reliant on external financing, as seen in positive financing cash flows.

Breakdown
TTM	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement		Total Revenue
0.00	0.00	1.98M	964.68K	3.89M	67.89K
	Gross Profit
-473.10K	0.00	-128.99K	-502.88K	-149.79K	-2.12M
	EBIT
-4.46M	-3.95M	-3.36M	-1.39M	-1.16M	-4.63M
	EBITDA
-1.44M	-3.53M	-335.87K	-101.42K	-77.02K	-4.45M
	Net Income Common Stockholders
-2.45M	-3.92M	-3.33M	-1.08M	-1.17M	-4.63M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
54.85K	2.97K	831.27K	506.35K	448.24K	653.68K
	Total Assets
533.53K	935.62K	1.17M	621.64K	2.67M	741.30K
	Total Debt
2.83M	2.77M	5.02M	4.41M	5.16M	3.39M
	Net Debt
2.77M	2.77M	4.18M	3.91M	4.72M	2.74M
	Total Liabilities
4.79M	5.28M	6.68M	5.09M	6.55M	4.61M
	Stockholders Equity
-4.26M	-4.35M	-5.51M	-4.47M	-3.88M	-3.87M
Cash Flow		Free Cash Flow
-2.23M	-2.33M	-234.08K	-1.08M	-2.98M	-1.90M
	Operating Cash Flow
-1.33M	0.00	-234.07K	-1.08M	-2.98M	-1.90M
	Investing Cash Flow
0.00	0.00	0.00	0.00	0.00	0.00
	Financing Cash Flow
2.01M	1.50M	559.00K	-421.37K	2.78M	2.16M

Arch Biopartners Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.76
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ARCH, the sentiment is Negative. The current price of 1.76 is below the 20-day moving average (MA) of 1.86, below the 50-day MA of 1.88, and below the 200-day MA of 1.76, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 36.11 is Neutral, neither overbought nor oversold. The STOCH value of 15.59 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ARCH.

Arch Biopartners Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	49 Neutral	$6.90B	-0.08	-53.01%	2.43%	24.84%	-3.06%
ONC	44 Neutral	$77.35M	―	-184.69%	―	―	27.78%
ARCH	21 Underperform	C$115.49M	―	90.17%	―	―	-78.59%